Using Queuing (and Simulation) to Reduce the Duration of Phase 1 Cancer Trials

Updated: Oct 9

“Phase 1 cancer studies, which guide dose selection for subsequent studies, are almost 3 times more prevalent than phase 3 studies and have a median study duration considerably longer than 2 years, which constitutes a major component of drug development time.”

It takes a long, long time for new cancer treatments to get through the necessary clinical trials and reach FDA approval. The median duration for phase 1 oncology trials is around 32 months, and late-stage trials (phases 2 and 3) have seen their times steadily rise in recent years. It stands to reason that if you can safely reduce trial duration, then these life-saving therapies can become available sooner.

But is there a safe and effective way to reduce phase 1 oncology trial duration?


To continue reading ....



4 views

Recent Posts

See All
Advent2Labs_Logo_300dpi.png
  • Facebook
(65) 62089575
(65)9101 6027
20 Kallang Avenue,
Level 6, Pico Creative Centre
SIngapore 339411
Facebook
Facebook